Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for BevacizumabYANXIONG MAO; KISS, Szilard; BOYER, Julie L et al.Human gene therapy. 2011, Vol 22, Num 12, pp 1525-1535, issn 1043-0342, 11 p.Article

Bevacizumab-induced hand-foot syndrome: circumscribed typeMUNEHIRO, A; YONEDA, K; YOKOMISE, H et al.British journal of dermatology (1951). 2010, Vol 162, Num 6, pp 1411-1413, issn 0007-0963, 3 p.Article

Injections sous-conjonctivales de bévacizumab dans le traitement de la néovascularisation cornéenne = Subconjunctival bevacizumab for corneal neovascularizationGUEUDRY, J; RICHEZ, F; TOUGERON-BROUSSEAU, B et al.Journal français d'ophtalmologie. 2010, Vol 33, Num 9, pp 630-636, issn 0181-5512, 7 p.Article

Le bévacizumab dans le traitement des radionécroses cérébrales = Bevacizumab for the treatment of cerebral radionecrosisGRONIER, S; BOURG, V; FRENAY, M et al.Revue neurologique (Paris). 2011, Vol 167, Num 4, pp 331-336, issn 0035-3787, 6 p.Article

Bevacizumab 5 mg/kg can be infused safely over 10 minutesREIDY, Diane L; CHUNG, Ki Y; TIMONEY, John P et al.Journal of clinical oncology. 2007, Vol 25, Num 19, pp 2691-2695, issn 0732-183X, 5 p.Article

Bevacizumab : current status and future directionsMIDGLEY, Rachel; KERR, David.Annals of oncology. 2005, Vol 16, Num 7, pp 999-1004, issn 0923-7534, 6 p.Article

Bevacizumab and irinotecan for recurrent oligodendroglial tumorsTAILLIBERT, S; VINCENT, L. A; DEHAIS, C et al.Neurology. 2009, Vol 72, Num 18, pp 1601-1606, issn 0028-3878, 6 p.Article

Localized skin necrosis by bevacizumabFRANCES, Laura; GUIJARRO, Jaime; LEIVA-SALINAS, Maria Del Carmen et al.EJD. European journal of dermatology. 2013, Vol 23, Num 2, pp 251-252, issn 1167-1122, 2 p.Article

Bevacizumab et radiothérapie = Bevacizumab and radiotherapyBLANCHARD, P; BESSE, B; DEUTSCH, E et al.Revue des maladies respiratoires. 2008, Vol 25, Num 10, pp 1319-1321, issn 0761-8425, 3 p.Article

CAN PEROPERATIVE BEVACIZUMAB IMPROVE TRABECULECTOMY OUTCOME? AVASTIN-TRAB STUDY : 2009 FRO PROJECTSVANDEWALLE, E; SPIELBERG, L; ZEYEN, T et al.Bulletin de la Société belge d'ophtalmologie. 2010, Num 314, pp 51-52, issn 0081-0746, 2 p.Article

Predictive Biomarkers for Bevacizumab: Are We There Yet?MARU, Dipen; VENOOK, Alan P; ELLIS, Lee M et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2824-2827, issn 1078-0432, 4 p.Article

Bevacizumab for Malignant GliomasIWAMOTO, Fabio M; FINE, Howard A.Archives of neurology (Chicago). 2010, Vol 67, Num 3, pp 285-288, issn 0003-9942, 4 p.Article

Bevacizumab in older patients and patients with poorer performance statusHOFF, Paulo M.Seminars in oncology. 2006, Vol 33, Num 5, issn 0093-7754, S19-S25, SUP10Article

Exudative, Nonhealing Scalp: A Complication of Systemic Chemotherapy With Capecitabine and BevacizumabBLACK, Jeanette M; HODARI, Kafele T; ROGERS, Nicole et al.Archives of dermatology (1960). 2011, Vol 147, Num 1, pp 134-135, issn 0003-987X, 2 p.Article

Tumeurs cérébrales primitives rares et thérapies cibléesTAILLIBERT, Sophie.Neurologie.com. 2010, Vol 2, pp 27-28, issn 2100-9511, 2 p., NS1Article

Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (Avastin) ― a South African perspectiveJANSEN, Rita-Marié; GOUWS, Chris.SAMJ. South African medical journal. 2009, Vol 99, Num 6, pp 446-449, issn 0256-9574, 4 p.Article

Bevacizumab Use for Recurrent High- Grade Glioma at McGill University HospitalSAHEBJAM, Solmaz; GAROUFALIS, Evgenia; GUIOT, Marie-Christine et al.Canadian journal of neurological sciences. 2013, Vol 40, Num 2, pp 241-246, issn 0317-1671, 6 p.Article

Erythrodermic Psoriasis Improved by Panitumumab, But Not BevacizumabNISHIZAWA, Aya; SATOH, Takahiro; YOKOZEKI, Hiroo et al.Acta dermato-venereologica. 2012, Vol 92, Num 4, pp 360-361, issn 0001-5555, 2 p.Article

Platelets take up the monoclonal antibody bevacizumabVERHEUL, Henk M. W; LOLKEMA, Martijn P. J; QIAN, David Z et al.Clinical cancer research. 2007, Vol 13, Num 18, pp 5341-5347, issn 1078-0432, 7 p., 1Article

Bevacizumab for recurrent ependymomaGREEN, R. M; CLOUGHESY, T. F; STUPP, R et al.Neurology. 2009, Vol 73, Num 20, pp 1677-1680, issn 0028-3878, 4 p.Article

Utilisation préférentielle du bevacizumab à la rechute: Pour ou contre ?DONNADIEU, Anne; DE LA MOTTE ROUGE, Thibault.Onko +. 2013, Vol 5, Num 40, pp 13-15, issn 2101-9495, 3 p., CAH2Article

Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosisBENOIT, Amandine; DUCRAY, François; CARTALAT-CAREL, Stéphanie et al.Journal of neurology. 2011, Vol 258, Num 2, pp 328-329, issn 0340-5354, 2 p.Article

Le traitement de la radionécrose du système nerveux central = Therapy for radiation necrosis of the central nervous systemPSIMARAS, D; FEUVRET, L; DUCRAY, F et al.La Lettre du neurologue. 2011, Vol 15, Num 3, pp 78-84, issn 1276-9339, 7 p.Article

Traitement du glaucome néovasculaire en 2012: apport des anti-VEGF = Neovascular glaucoma treatment in 2012: Role of anti-VEGF agentsKODJIKIAN, L.Journal français d'ophtalmologie. 2013, Vol 36, Num 5, pp 461-465, issn 0181-5512, 5 p.Conference Paper

Antiangiogenic Therapy for Cancer: An UpdateAL-HUSEIN, Belal; ABDALLA, Maha; TREPTE, Morgan et al.Pharmacotherapy. 2012, Vol 32, Num 12, pp 1095-1111, issn 0277-0008, 17 p.Article